PharmacoEconomics

, Volume 29, Issue 11, pp 989–1009 | Cite as

Rotavirus Vaccine RIX4414 (Rotarix™)

A Pharmacoeconomic Review of its Use in the Prevention of Rotavirus Gastroenteritis in Developing Countries
Adis Pharmacoeconomic Drug Evaluation Rotavirus Vaccine RIX4414: A Pharmacoeconomic Review

Abstract

This article provides an overview of the clinical profile of rotavirus vaccine RIX4414 (Rotarix™) in the prevention of rotavirus gastroenteritis (RVGE) in developing countries, followed by a comprehensive review of pharmacoeconomic analyses with the vaccine in low- and middle-income countries.

RVGE is associated with significant morbidity and mortality among children <5 years of age in developing countries. The protective efficacy of a two-dose oral series of rotavirus vaccine RIX4414 has been demonstrated in several well designed clinical trials conducted in developing countries, and the ‘real-world’ effectiveness of the vaccine has also been shown in naturalistic and case-control trials after the introduction of universal vaccination programmes with RIX4414 in Latin American countries. The WHO recommends universal rotavirus vaccination programmes for all countries.

Numerous modelled cost-effectiveness analyses have been conducted with rotavirus vaccine RIX4414 across a wide range of low- and middle-income countries. Although data sources and assumptions varied across studies, results of the analyses consistently showed that the introduction of the vaccine as part of a national vaccination programme would be very (or highly) cost effective compared with no rotavirus vaccination programme, according to widely used costeffectiveness thresholds for developing countries. Vaccine price was not known at the time the analyses were conducted and had to be estimated. In sensitivity analyses, rotavirus vaccine RIX4414 generally remained cost effective at the highest of a range of possible vaccine prices considered. Despite these favourable results, decisions regarding the implementation of universal vaccination programmes with RIX4414 may also be contingent on budgetary and other factors, underscoring the importance of subsidized vaccination programmes for poor countries through the GAVI Alliance (formerly the Global Alliance for Vaccines and Immunization).

References

  1. 1.
    Parashar UD, Hummelman EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003 May; 9 (5): 565–72PubMedCrossRefGoogle Scholar
  2. 2.
    Leung AK, Kellner JD, Davies HD. Rotavirus gastroenteritis. Adv Ther 2005; 22 (5): 476–87PubMedCrossRefGoogle Scholar
  3. 3.
    Cortese MM, Parashar UD, Centers for Disease Control and Prevention (CDC). Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWRRecomm Rep 2009 Feb 6; 58 (RR-2): 1–25Google Scholar
  4. 4.
    Parashar UD, Alexander JP, Glass RI. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWRRecomm Rep 2006 Aug 11; 55 (RR-12): 1–13Google Scholar
  5. 5.
    Gray J, Vesikari T, Van Damme P, et al. Rotavirus. J Pediatr Gastroenterol Nutr 2008 May; 46 Suppl.2: S24–31CrossRefGoogle Scholar
  6. 6.
    Clark HF, Offit PA. Vaccines for rotavirus gastroenteritis universally needed for infants. Pediatr Ann 2004 Aug; 33 (8): 536–43PubMedGoogle Scholar
  7. 7.
    Soriano-Gabarro M, Mrukowicz J, Vesikari T, et al. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006; 25 Suppl.1: S7–11Google Scholar
  8. 8.
    Grimwood K, Lambert SB, Milne RJ. Rotavirus infections and vaccines: burden of illness and potential impact of vaccination. Pediatr Drugs 2010; 12 (4): 235–56CrossRefGoogle Scholar
  9. 9.
    Parashar UD, Gibson CJ, Bresse JS, et al. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006 Feb; 12 (2): 304–6PubMedCrossRefGoogle Scholar
  10. 10.
    Velazquez FR. Protective effects of natural rotavirus infection. Pediatr Infect Dis J 2009 Mar; 28 (3 Suppl.): S54–6Google Scholar
  11. 11.
    Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005; 15 (1): 29–56PubMedCrossRefGoogle Scholar
  12. 12.
    Diez-Domingo J, Baldo J-M, Patrzalek M, et al. Primary care-based surveillance to estimate the burden of rotavirus gastroenteritis among children aged less than 5 years in six European countries. Eur J Pediatr 2011 Feb; 170 (2): 213–22PubMedCrossRefGoogle Scholar
  13. 13.
    Van Damme P, Giaquinto C, Huet F, et al. Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study. J Infect Dis 2007 May 1; 195 Suppl.1: S4–16CrossRefGoogle Scholar
  14. 14.
    Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996 Oct 3; 335 (14): 1022–8PubMedCrossRefGoogle Scholar
  15. 15.
    Bhan MK, Lew JF, Sazawal S, et al. Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea. J Infect Dis 1993 Aug; 168 (2): 282–7PubMedCrossRefGoogle Scholar
  16. 16.
    Bishop RF, Barnes GL, Cipriani E, et al. Clinical immunity after neonatal rotavirus infection: a prospective longitudinal study in young children. N Engl J Med 1983 Jul 14; 309 (2): 72–6PubMedCrossRefGoogle Scholar
  17. 17.
    Vesikari T, Van Damme P, Giaquinto C, et al. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe. J Pediatr Gastroenterol Nutr 2008 May; 46 Suppl.2: S38–48CrossRefGoogle Scholar
  18. 18.
    American Academy of Pediatrics Committee on Infectious Diseases. Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine. Pediatrics 2009 May; 123 (5): 1412–20CrossRefGoogle Scholar
  19. 19.
    Vesikari T, Van Damme P, Giaquinto C, et al. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe: executive summary. J Pediatr Gastroenterol Nutr 2008 May; 46 (5): 615–8PubMedCrossRefGoogle Scholar
  20. 20.
    Global Advisory Committee on Vaccine Safety. Report of meeting held 17-18 June 2009. Wkly Epidemiol Rec 2009 Aug 7; 84 (32): 325–32Google Scholar
  21. 21.
    World Health Organization. Meeting of the immunization Strategic Advisory Group of Experts, April 2009: conclusions and recommendations. Wkly Epidemiol Rec 2009 Jun 5; 84: 220–35Google Scholar
  22. 22.
    World Health Organization. Global use of rotavirus vaccines recommended [media release; online]. Available from URL: http://www.who.int/mediacentre/news/releases/2009/rotavirus_vaccines_20090605/en/index.html# [Accessed 2011 May 24]Google Scholar
  23. 23.
    McCormack PL, Keam SJ. Rotavirus vaccine RIX4414 (Rotarix™): a review of its use in the prevention of rotavirus gastroenteritis. Paediatr Drugs 2009; 11 (1): 75–88PubMedCrossRefGoogle Scholar
  24. 24.
    Plosker GL. Pentavalent rotavirus vaccine (RotaTeq®): a review of its use in the prevention of rotavirus gastroenteritis in Europe. Drugs 2010 Jun 18; 70 (9): 1165–88PubMedCrossRefGoogle Scholar
  25. 25.
    Babar ZU, Scahill S. Is there a role for pharmacoeconomics in developing countries? Pharmacoeconomics 2010; 28 (12): 1069–74PubMedCrossRefGoogle Scholar
  26. 26.
    Shafie AA, Hassali MA. Is there a role for pharmacoeconomics in developing countries? [letter; author reply 84-86]. Pharmacoeconomics 2011; 29 (1): 83–84PubMedCrossRefGoogle Scholar
  27. 27.
    World Bank. World Bank list of economics (January 2011) [online]. Available from URL: http://siteresources.worldbank.org/DATASTATISTICS/Resources/CLASS.XLS [Accessed 2011 May 24]
  28. 28.
    Plosker GL. Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developed countries. Pharmacoeconomics 2011; 29 (5): 439–54PubMedCrossRefGoogle Scholar
  29. 29.
    Parashar UD, Burton A, Lanata C, et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009; 200 Suppl.1: S9–15CrossRefGoogle Scholar
  30. 30.
    Danchin MH, Bines JE. Defeating rotavirus? The global recommendation for rotavirus vaccination. N Engl J Med 2009; 361 (20): 1919–21Google Scholar
  31. 31.
    Tate JE, Chitambar S, Esposito DH, et al. Disease and economic burden of rotavirus diarrhoea in India. Vaccine 2009 Nov 20; 27 Suppl.5: F18–24CrossRefGoogle Scholar
  32. 32.
    Nelson EAS, Walker DG. Reaching MDG 4 in India: a role for rotavirus vaccine? Clin Infect Dis 2011; 52 (2): 178–9PubMedCrossRefGoogle Scholar
  33. 33.
    Sanchez-Padilla E, Grais RF, Guerin PJ, et al. Burden of disease and circulating serotypes of rotavirus infection in sub-Saharan Africa: systematic review and meta-analysis. Lancet Infect Dis 2009 Sep; 9 (9): 567–76PubMedCrossRefGoogle Scholar
  34. 34.
    Kiulia NM, Kamenwa R, Irimu G, et al. The epidemiology of human rotavirus associated with diarrhoea in Kenyan children: a review. J Trop Pediatr 2008 Dec; 54 (6): 401–5PubMedCrossRefGoogle Scholar
  35. 35.
    de Oliveira LH, Danovaro-Holliday MC, Andrus JK, et al. Sentinel hospital surveillance for rotavirus in Latin American and Caribbbean countries. J Infect Dis 2009 Nov 1; 200 Suppl.1: S131–9CrossRefGoogle Scholar
  36. 36.
    de Oliveira LH, Danovaro-Holliday MC, Matus CR, et al. Rotavirus vaccine introduction in theAmericas: progress and lessons learned. Expert Rev Vaccines 2008 Apr; 7 (3): 345–53PubMedCrossRefGoogle Scholar
  37. 37.
    Meszner Z, Balogh A, Banyai K, et al. The clinical burden of rotavirus disease: retrospective analysis of infant and childhood gastroenteritis in seven countries in central and eastern Europe. Pediatr Infect Dis J 2008; 27 Suppl.1: S33–41Google Scholar
  38. 38.
    Ceyhan M, Alhan E, Salman N, et al. Multicenter prospective study on the burden of rotavirus gastroenteritis in Turkey, 2005-2006: a hospital-based study. J Infect Dis 2009 Nov 1; 200 Suppl.1: S234–8CrossRefGoogle Scholar
  39. 39.
    Centenari C, Gurgel RQ, Bohland AK, et al. Rotavirus vaccination in northeast Brazil: a laudable intervention, but can it lead to cost-savings? Vaccine 2010; 28 (25): 4162–8PubMedCrossRefGoogle Scholar
  40. 40.
    Granados-Garcia V, Velazquez-Castillo R, Garduno-Espinosa J, et al. Resource utilization and costs of treating severe rotavirus diarrhea in young Mexican children from the health care provider perspective. Rev Invest Clin 2009; 61 (1): 18–25PubMedGoogle Scholar
  41. 41.
    De la Hoz F, Alvis N, Narvaez J, et al. Potential epidemiological and economical impact of two rotavirus vaccines in Colombia. Vaccine 2010 May 14; 28 (22): 3856–64PubMedCrossRefGoogle Scholar
  42. 42.
    Ehrenkranz P, Lanata CF, Penny ME, et al. Rotavirus diarrhea disease burden in Peru: the need for a rotavirus vaccine and its potential cost savings. Rev Panam Salud Publica 2001 Oct; 10 (4): 240–8PubMedCrossRefGoogle Scholar
  43. 43.
    Rheingans RD, Constenla D, Antil L, et al. Economic and health burden of rotavirus gastroenteritis for the 2003 birth cohort in eight Latin American and Caribbean countries. Rev Panam Salud Publica 2007 Apr; 21 (4): 192–204PubMedCrossRefGoogle Scholar
  44. 44.
    Amador JJ, Vasquez J, Orozco M, et al. Rotavirus disease burden, Nicaragua 2001-2005: defining the potential impact of a rotavirus vaccination program. Int J Infect Dis 2010 Jul 1; 14 (7): e592–5CrossRefGoogle Scholar
  45. 45.
    Aikins M, Armah G, Akazili J, et al. Hospital health care cost of diarrheal disease in Northern Ghana. J Infect Dis 2010 Sep 1; 202 Suppl.: S126–30CrossRefGoogle Scholar
  46. 46.
    Tate JE, Kisakye A, Mugyenyi P, et al. Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda. Vaccine 2011 Jan 14; 29: 3329–34PubMedCrossRefGoogle Scholar
  47. 47.
    Nelson EA, Bresee JS, Parashar UD, et al. Rotavirus epidemiology: the Asian Rotavirus Surveillance Network. Vaccine 2008 Jun 19; 26 (26): 3192–6PubMedCrossRefGoogle Scholar
  48. 48.
    Widdowson M-A, Steele D, Vojdani J, et al. Global rotavirus surveillance: determining the need and measuring the impact of rotavirus vaccines. J Infect Dis 2009; 200 Suppl. 1: S1–8CrossRefGoogle Scholar
  49. 49.
    D’Souza RM, Hall G, Becker NG. Climatic factors associated with hospitalizations for rotavirus diarrhoea in children under 5 years of age. Epidemiol Infect 2008 Jan; 136 (1): 56–64PubMedCrossRefGoogle Scholar
  50. 50.
    Levy K, Hubbard AE, Eisenberg JN. Seasonality of rotavirus disease in the tropics: a systematic review and metaanalysis. Int J Epidemiol 2009 Dec; 38 (6): 1487–96PubMedCrossRefGoogle Scholar
  51. 51.
    Linhares AC, Velazquez FR, Perez-Schael I, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008 Apr 5; 371 (9619): 1181–9PubMedCrossRefGoogle Scholar
  52. 52.
    Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010 Jan 28; 362 (4): 289–98PubMedCrossRefGoogle Scholar
  53. 53.
    Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006 Jan; 354 (1): 11–22PubMedCrossRefGoogle Scholar
  54. 54.
    Tregnaghi MW, Abate HJ, Valencia A, et al. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatr Infect Dis J 2011; 30 (6): e103–8Google Scholar
  55. 55.
    Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990; 22 (3): 259–67PubMedCrossRefGoogle Scholar
  56. 56.
    Soares-Weiser K, Maclehose H, Ben-Aharon I, et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev 2010; 5: CD008521Google Scholar
  57. 57.
    De Vos B, Vesikari T, Linhares AC, et al.Arotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr Infect Dis J 2004 Oct; 23 (10 Suppl.): S179–82Google Scholar
  58. 58.
    Salinas B, Perez Schaeil I, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebocontrolled trial in Latin American infants. Pediatr Infect Dis J 2005 Sep; 24 (9): 807–16PubMedCrossRefGoogle Scholar
  59. 59.
    Gurgel RG, Bohland AK, Vieira SC, et al. Incidence of rotavirus and all-cause diarrhea in northeast Brazil following the introduction of a national vaccination program. Gastroenterology 2009 Dec; 137 (6): 1970–5PubMedCrossRefGoogle Scholar
  60. 60.
    Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med 2010 Jan 28; 362 (4): 299–305PubMedCrossRefGoogle Scholar
  61. 61.
    Quintanar-Solares M, Yen C, Richardson V, et al. Impact of rotavirus vaccination on diarrhea-related hospitalizations among children <5 years of age in Mexico. Pediatr Infect Dis J 2011 Jan; 30 (1 Suppl.): S11–5Google Scholar
  62. 62.
    Yen C, Armero Guardado JA, Alberto P, et al. Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador. Pediatr Infect Dis J 2011 Jan; 30 (1 Suppl.): S6–10Google Scholar
  63. 63.
    de Palma O, Cruz L, Ramos H, et al. Effectivenessof rotavirus vaccination against childhood diarrhoea in El Salvador: casecontrol study. BMJ 2010 Jun 15; 340: c2825CrossRefGoogle Scholar
  64. 64.
    Correia JB, Patel MM, Nakagomi O, et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. J Infect Dis 2010 Feb 1; 201 (3): 363–9PubMedCrossRefGoogle Scholar
  65. 65.
    GlaxoSmithKline. Rotarix (rotavirus vaccine, live, oral) US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2011 FebGoogle Scholar
  66. 66.
    GlaxoSmithKline Biologicals s.a.. Rotarix® EU summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000639/WC500054789.pdf [Accessed 2011 Mar 14]Google Scholar
  67. 67.
    Atherly D, Dreibelbis R, Parashar UD, et al. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries. J Infect Dis 2009 Nov 1; 200 Suppl. 1: S28–38CrossRefGoogle Scholar
  68. 68.
    Berry SA, Johns B, Shih C, et al. The cost-effectiveness of rotavirus vaccination in Malawi. J Infect Dis 2010 Sep; 202 Suppl.: S108–15CrossRefGoogle Scholar
  69. 69.
    Clark AD, Walker DG, Mosqueira NR, et al. Costeffectiveness of rotavirus vaccination in Peru. J Infect Dis 2009 Nov 1; 200 Suppl. 1: S114–24CrossRefGoogle Scholar
  70. 70.
    Constenla DO, Linhares AC, Rheingans RD, et al. Economic impact of a rotavirus vaccine in Brazil. J Health Popul Nutr 2008 Dec; 26 (4): 388–96PubMedGoogle Scholar
  71. 71.
    Constenla D, Velazquez FR, Rheingans RD, et al. Economic impact of a rotavirus vaccination program in Mexico. Rev Panam Salud Publica 2009 Jun; 25 (6): 481–90PubMedCrossRefGoogle Scholar
  72. 72.
    Esposito DH, Tate JE, Kang G, et al. Projected impact and cost-effectiveness of a rotavirus vaccination program in India, 2008. Clin Infect Dis 2011; 52 (2): 171–7PubMedCrossRefGoogle Scholar
  73. 73.
    Podewils LJ, Antil L, Hummelman E, et al. Projected cost-effectiveness of rotavirus vaccination for children in Asia. J Infect Dis 2005 Sep 1; 192 Suppl.1: S133–45CrossRefGoogle Scholar
  74. 74.
    Ortega O, El-Sayed N, Sanders JW, et al. Cost-benefit analysis of a rotavirus immunization program in the Arab Republic of Egypt. J Infect Dis 2009 Nov 1; 200 Suppl.1: S92–8CrossRefGoogle Scholar
  75. 75.
    Chotivitayatarakorn P, Chotivitayatarakorn P, Poovorawan Y. Cost-effectiveness of rotavirus vaccination as part of the national immunization program for Thai children. Southeast Asian J Trop Med Public Health 2010 Jan; 41 (1): 114–25PubMedGoogle Scholar
  76. 76.
    Isakbaeva ET, Musabaev E, Antil L, et al. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. Vaccine 2007 Jan 4; 25 (2): 373–80PubMedCrossRefGoogle Scholar
  77. 77.
    Tate JE, Rheingans RD, O’Reilly CE, et al. Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in Kenya. J Infect Dis 2009 Nov 1; 200 Suppl.1: S76–84CrossRefGoogle Scholar
  78. 78.
    Wang XY, Riewpaiboon A, von Seidlein L, et al. Potential cost-effectiveness of a rotavirus immunization program in rural China. Clin Infect Dis 2009 Oct 15; 49 (8): 1202–10PubMedCrossRefGoogle Scholar
  79. 79.
    de Soaárez PC, Valentim J, Sartori AM, et al. Cost-effectiveness analysis of routine rotavirus vaccination in Brazil. Rev Panam Salud Publica 2008 Apr; 23 (4): 221–30CrossRefGoogle Scholar
  80. 80.
    Fischer TK, Anh DD, Antil L, et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J Infect Dis 2005 Nov 15; 192 (10): 1720–6PubMedCrossRefGoogle Scholar
  81. 81.
    Flem ET, Latipov R, Nurmatov ZS, et al. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in Kyrgyzstan. J Infect Dis 2009 Nov 1; 200 Suppl.1: S195–202CrossRefGoogle Scholar
  82. 82.
    Kim SY, Goldie SJ, Salomon JA. Cost-effectiveness of Rotavirus vaccination in Vietnam. BMC Public Health 2009; 9: 29PubMedCrossRefGoogle Scholar
  83. 83.
    Rheingans RD, Antil L, Dreibelbis R, et al. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. J Infect Dis 2009 Nov 1; 200 Suppl. 1: S16–27CrossRefGoogle Scholar
  84. 84.
    Rose J, Hawthorn RL, Watts B, et al. Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. uBMJ 2009; 339: b3653Google Scholar
  85. 85.
    Wilopo SA, Kilgore P, Kosen S, et al. Economic evaluation of a routine rotavirus vaccination programme in Indonesia. Vaccine 2009 Nov 20; 27 Suppl.5: F67–74CrossRefGoogle Scholar
  86. 86.
    Kim SY, Sweet S, Slichter D, et al. Health and economic impact of rotavirus vaccination in GAVI-eligible countries. BMC Public Health 2010; 10: 253PubMedCrossRefGoogle Scholar
  87. 87.
    Murray CJL, Lopez AD. The global burden of disease. Vol. I of global burden of disease and injury series. Cambridge (MA): Harvard University Press, 1996Google Scholar
  88. 88.
    Meeting of the Immunization Strategic Advisory Group of Experts, April 2009: conclusions and recommendations. Wkly Epidemiol Rec 2009; 84 (23): 220–36Google Scholar
  89. 89.
    Ladabaum U. Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications. Aliment Pharmacol Ther 2003 Apr; 17 (8): 1021–30PubMedCrossRefGoogle Scholar
  90. 90.
    Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006 Jan 5; 354 (1): 23–33PubMedCrossRefGoogle Scholar
  91. 91.
    World Health Organization. Rotavirus vaccines: an update. Wkly Epidemiol Rec 2009; 84: 533–40Google Scholar
  92. 92.
    Bernstein DI, Sack DA, Reisinger K, et al. Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants. J Infect Dis 2002 Nov 15; 186 (10): 1487–9PubMedCrossRefGoogle Scholar
  93. 93.
    Rotavirus vaccine - AVANT immunotherapeutics/Glaxo-SmithKline: 89-12, RIX4414. Drugs R D 2004; 5: 113–5Google Scholar
  94. 94.
    Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004 Oct; 23 (10): 937–43PubMedCrossRefGoogle Scholar
  95. 95.
    World Health Organization. Some strategies to reduce risk. In: WHO. The world health report 2002: reducing risks, promoting healthy life. Geneva: WHO, 2002 [online]. Available from URL: http://www.who.int/whr/2002/en/ [Accessed 2011 Jun 28]Google Scholar
  96. 96.
    World Bank. World development report 1993: investing in health. Washington, DC: Oxford University Press, 1993CrossRefGoogle Scholar
  97. 97.
    Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 2008; 26 (3): 191–215PubMedCrossRefGoogle Scholar
  98. 98.
    Bauch CT, Anonychuk AM, Van Effelterre T, et al. Incorporating herd immunity effects into cohort models of vaccine cost-effectiveness. Med Decis Making 2009; 29 (5): 557–69PubMedCrossRefGoogle Scholar
  99. 99.
    Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making 2003; 23 (1): 76–82PubMedCrossRefGoogle Scholar
  100. 100.
    Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Making 2006; 26 (5): 434–46PubMedCrossRefGoogle Scholar
  101. 101.
    Mangen MJ, van Duynhoven YT, Vennema H, et al. Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program? Vaccine 2010 Mar 19; 28 (14): 2624–35PubMedCrossRefGoogle Scholar
  102. 102.
    Jit M, Bilcke J, Mangen MJ, et al. The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine 2009 Oct 19; 27 (44): 6121–8PubMedCrossRefGoogle Scholar
  103. 103.
    de Blasio BF, Kasymbekova K, Flem E. Dynamic model of rotavirus transmission and the impact of rotavirus vaccination in Kyrgyzstan. Vaccine 2010 Nov 23; 28 (50): 7923–32PubMedCrossRefGoogle Scholar
  104. 104.
    Shim E, Galvani AP. Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination. Vaccine 2009 Jun 19; 27 (30): 4025–30PubMedCrossRefGoogle Scholar
  105. 105.
    Pitzer VE, Viboud C, Simonsen L, et al. Demographic variability, vaccination, and the spatiotemporal dynamics of rotavirus epidemics. Science 2009 Jul 17; 325 (5938): 290–4PubMedCrossRefGoogle Scholar
  106. 106.
    World Health Organization. WHO guide for standardization of economic evaluations of immunization programmes [online]. Available from URL: http://www.who.int/immunization_financing/tools/who_ivb_08_14_en.pdf [Accessed 2011 Sep 6]Google Scholar
  107. 107.
    Patel MM, Steele D, Gentsch JR, et al. Real-world impact of rotavirus vaccination. Pediatr Infect Dis J 2011 Jan; 30 Suppl.1: S1–5Google Scholar
  108. 108.
    Tate JE, Cortese MM, Payne DC, et al. Uptake, impact, and effectiveness of rotavirus vaccination in the United States. Pediatr Infect Dis J 2011 Jan; 30 Suppl. 1: S56–60Google Scholar
  109. 109.
    Monto AS. Epidemiology of influenza. Vaccine 2008 Sep 12; 26 Suppl. 4: D45–8CrossRefGoogle Scholar
  110. 110.
    Centers for Disease Control and Prevention (CDC). Respiratory syncytial virus activity: United States, July 2007-December 2008. MMWR Morb Mortal Wkly Rep 2008 Dec 19; 57 (50): 1355–8Google Scholar
  111. 111.
    Tu HA, Woerdenbag HJ, Kane S, et al. Economic evaluations of rotavirus immunization for developing countries: a review of the literature. Expert Rev Vaccines 2011; 10 (7): 1037–51PubMedCrossRefGoogle Scholar
  112. 112.
    Postma MJ, Jit M, Rozenbaum MH, et al. Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs: a generic approach applied to various regions in the world. BMC Med 2011; 9: 84PubMedCrossRefGoogle Scholar
  113. 113.
    Valencia-Mendoza A, Bertozzi SM, Gutierrez JP, et al. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico. BMC Infect Dis 2008; 8: 103PubMedCrossRefGoogle Scholar
  114. 114.
    Shillcutt SD, Walker DG, Goodman CA, et al. Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics 2009; 27 (11): 903–17PubMedCrossRefGoogle Scholar
  115. 115.
    GAVI. GAVI welcomes lower prices for life-saving vaccines: manufacturer commitments will help GAVI vaccinate millions of children in least-developed countries [media release]. 2011 Jun 6 [online]. Available from URL: http://www.gavialliance.org/library/news/press-releases/2011/gavi-welcomes-lower-prices-for-life-saving-vaccines [Accessed 2011 Sep 2]Google Scholar
  116. 116.
    Connolly M, Topachevskyi O, Standaert B, et al. The impact of rotavirus vaccination on discounted net tax revenue in Egypt: a government perspective analysis. Pharmacoeconomics. In pressGoogle Scholar

Copyright information

© Springer International Publishing AG 2011

Authors and Affiliations

  1. 1.Adis, a Wolters Kluwer BusinessAucklandNew Zealand

Personalised recommendations